- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00610727
Staccato Prochlorperazine Single Dose PK Study
October 29, 2020 updated by: Alexza Pharmaceuticals, Inc.
Tolerability, Safety and Pharmacokinetics of a Single Dose of Staccato™ Prochlorperazine for Inhalation in Normal, Healthy Volunteers
The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of inhaled prochlorperazine
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of a single, inhaled dose of prochlorperazine (PCZ), administered as 1 or 2 puffs in healthy young volunteers.
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78704-7016
- PPD Phase I Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects will be male or female subjects between the ages 18 to 45 years, inclusive in good general health as determined by medical history, physical examination, 12-lead ECG, spirometry, blood chemistry profile, hematology, urinalysis and in the opinion of the Principal Investigator.
Exclusion Criteria:
- Subjects with a known history of allergy or intolerance to phenothiazines or related drugs or who have any disease, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inhaled prochlorperazine 0.625 mg vs IV
Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg
|
IV Prochlorperazine for bioavailability
Other Names:
Inhaled Staccato Prochlorperazine 0.625 mg
Other Names:
Prochlorperazine 10 mg IV over 5 sec for patient qualification
Other Names:
|
Experimental: Inhaled prochlorperazine 1.25 mg
Inhaled Staccato prochlorperazine 1.25 mg
|
Inhaled Staccato Prochlorperazine 1.25 mg
Other Names:
|
Experimental: Inhaled prochlorperazine 2.5 mg
Inhaled Staccato prochlorperazine 2.5 mg
|
Inhaled Staccato Prochlorperazine 2.5 mg
Other Names:
|
Experimental: Inhaled prochlorperazine 5 mg
Inhaled Staccato prochlorperazine 5 mg
|
InhaledStaccato Prochlorperazine 5 mg
Other Names:
|
Experimental: Inhaled prochlorperazine 10 mg
Inhaled Staccato prochlorperazine 10 mg
|
InhaledStaccato Prochlorperazine 10 mg
Other Names:
|
Placebo Comparator: inhaled Placebo
inhaled Staccato Placebo (0 mg)
|
Inhaled Staccato Placebo (0 mg)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Peak (Tmax)
Time Frame: 24 hours
|
Time from dose to peak prochlorperazine concentration
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute Bioavailability of Inhaled Prochlorperazine
Time Frame: 24 hours
|
Absolute bioavailability of inhaled prochlorperazine via AUC infinity
|
24 hours
|
Dose Proportionality of Inhaled Prochlorperazine by Power Analysis
Time Frame: 24 hours
|
Dose proportionality by power analysis examines the linear regression of the log-AUC versus log-Dose on a by-patient basis across all doses administered.
The slope and 90% confidence interval (CI) provide a clear, quantitative (best practices) assessment of the relationship of drug delivered to dose administered.
The units on such analyses are generally those of slope (rise over run), with 1.000 being "perfect".
Although any positive slope might be considered clinically useful, a 90% CI within the criteria of 0.800-1.250
may be considered a delivery system which is "as good as it gets".
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Daniel A Spyker, MD, Alexza Pharmaceuticals, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2004
Primary Completion (Actual)
October 1, 2004
Study Completion (Actual)
October 1, 2004
Study Registration Dates
First Submitted
January 28, 2008
First Submitted That Met QC Criteria
January 28, 2008
First Posted (Estimate)
February 8, 2008
Study Record Updates
Last Update Posted (Actual)
October 30, 2020
Last Update Submitted That Met QC Criteria
October 29, 2020
Last Verified
September 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Dopamine Agents
- Dopamine Antagonists
- Prochlorperazine
Other Study ID Numbers
- AMDC-004-001
- Amended September 8, 2004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
IPD submitted to regulatory authorities.
Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Prochlorperazine 0.5 mg IV over 5 sec
-
William Sikov MDThe Miriam Hospital; Rhode Island Hospital; Memorial Hospital of Rhode IslandCompletedRectal Cancer | Colon CancerUnited States
-
Alexza Pharmaceuticals, Inc.CompletedMigraine Headache, With or Without AuraUnited States
-
Montefiore Medical CenterNational Institute on Aging (NIA)Completed
-
Beni-Suef UniversityCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Unknown
-
ShireCompleted
-
Helsinn Healthcare SAActive, not recruitingChemotherapy-induced Nausea and VomitingSpain, Germany, Switzerland, China, Czechia, United Kingdom, Greece
-
University of Texas Southwestern Medical CenterTerminated
-
Brown UniversityLifespan; SouthCoast Medical Group; Memorial hospitalCompletedMetastatic Pancreatic CancerUnited States
-
AstraZenecaTerminatedType 2 DiabetesFrance, Korea, Republic of, South Africa, Spain, United Kingdom, Vietnam, Norway, Israel, Philippines, Australia